Adaptimmune Plots Path to FDA as Sarcoma Cell Therapy Aces Pivotal Trial

Following strong treatment response data for Adaptimmune’s lete-cel, the biotech is planning to initiate a rolling BLA submission to the FDA, set to start by the end of 2025.